celecoxib has been researched along with triflupromazine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Aldib, I; Chikh Alard, I; De Carvalho, A; Dufrasne, F; Flemmig, J; Furtmüller, PG; Gelbcke, M; Mathieu, V; Meyer, F; Nève, J; Obinger, C; Prévost, M; Rousseau, A; Soubhye, J; Tadrent, S; Van Antwerpen, P; Zouaoui Boudjeltia, K | 1 |
2 other study(ies) available for celecoxib and triflupromazine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
Topics: Benzimidazoles; Cell Line; Databases, Chemical; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glutamic Acid; Glutamine; Guanidines; Humans; Hydrogen Peroxide; Kinetics; Lactoperoxidase; Lipoproteins, LDL; Models, Chemical; Molecular Docking Simulation; Neutrophils; Oxidation-Reduction; Peroxidase; Quinazolines; Stereoisomerism | 2017 |